CRBP vs. TBPH, TERN, NRIX, GYRE, ARVN, ERAS, GHRS, MGTX, SNDL, and ESPR
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), Arvinas (ARVN), Erasca (ERAS), GH Research (GHRS), MeiraGTx (MGTX), SNDL (SNDL), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs. Its Competitors
Corbus Pharmaceuticals (NASDAQ:CRBP) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.
Corbus Pharmaceuticals has higher earnings, but lower revenue than Theravance Biopharma. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.
Corbus Pharmaceuticals currently has a consensus price target of $45.43, indicating a potential upside of 178.36%. Theravance Biopharma has a consensus price target of $23.00, indicating a potential upside of 65.23%. Given Corbus Pharmaceuticals' higher possible upside, equities analysts clearly believe Corbus Pharmaceuticals is more favorable than Theravance Biopharma.
64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Theravance Biopharma had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Theravance Biopharma and 4 mentions for Corbus Pharmaceuticals. Theravance Biopharma's average media sentiment score of 0.69 beat Corbus Pharmaceuticals' score of 0.62 indicating that Theravance Biopharma is being referred to more favorably in the news media.
Theravance Biopharma has a net margin of 16.88% compared to Corbus Pharmaceuticals' net margin of 0.00%. Theravance Biopharma's return on equity of 6.93% beat Corbus Pharmaceuticals' return on equity.
Summary
Theravance Biopharma beats Corbus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 10/13/2025 by MarketBeat.com Staff
